The planning award funds were entirely dedicated to the establishment of the disease team for the full award submission. This has included:
– Hiring the project leader, Dr. Phyllis Wu.
– Organization of the cell therapy manufacturing, quality assurance, and clinical groups.
– A meeting of the external advisory board.
– A site visit to the lentiviral vector manufacturing facility.
With these activities we were able to assemble and submit the full CIRM DT-2 application to pursue a translational research project based on the genetic programming of hematopoietic stem cells to become cancer-targeted by the insertion of T cell receptor (TCR) genes.